רוזובסטטין טבע ® 5 מ"ג ישראל - עברית - Ministry of Health

רוזובסטטין טבע ® 5 מ"ג

teva pharmaceutical indust.ltd - rosuvastatin as calcium 5 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

רוזובסטטין טבע ® 10 מ"ג ישראל - עברית - Ministry of Health

רוזובסטטין טבע ® 10 מ"ג

teva pharmaceutical indust.ltd - rosuvastatin as calcium 10 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

רוזובסטטין טבע ® 20 מ"ג ישראל - עברית - Ministry of Health

רוזובסטטין טבע ® 20 מ"ג

teva pharmaceutical indust.ltd - rosuvastatin as calcium 20 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

רוזובסטטין טבע ® 40 מ"ג ישראל - עברית - Ministry of Health

רוזובסטטין טבע ® 40 מ"ג

teva pharmaceutical indust.ltd - rosuvastatin as calcium 40 mg - tablets - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

פרוקטוצורין-N ישראל - עברית - Ministry of Health

פרוקטוצורין-n

teva pharmaceutical indust.ltd - allantoin 2 %; aluminium acetotartrate 0.4 % - ointment - benzocaine - for the relief of pain and inflammation caused by hemorrhoids.

ראלוקסיפן טבע ® ישראל - עברית - Ministry of Health

ראלוקסיפן טבע ®

teva pharmaceutical indust.ltd - raloxifene hydrochloride 60 mg - tablets - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .

טולטרודין E.R טבע ® 2 מ"ג ישראל - עברית - Ministry of Health

טולטרודין e.r טבע ® 2 מ"ג

teva pharmaceutical indust.ltd - tolterodine tartrate 2 mg - capsules - tolterodine - for the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.

טולטרודין E.R טבע ® 4 מ"ג ישראל - עברית - Ministry of Health

טולטרודין e.r טבע ® 4 מ"ג

teva pharmaceutical indust.ltd - tolterodine tartrate 4 mg - capsules - tolterodine - for the treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence.

סוליפנאצין טבע ® 5 מ"ג ישראל - עברית - Ministry of Health

סוליפנאצין טבע ® 5 מ"ג

teva pharmaceutical indust.ltd - solifenacin succinate 5 mg - tablets - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

סוליפנאצין טבע ® 10 מ"ג ישראל - עברית - Ministry of Health

סוליפנאצין טבע ® 10 מ"ג

teva pharmaceutical indust.ltd - solifenacin succinate 10 mg - tablets - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.